Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 13 de 13
Filtre
1.
J. appl. oral sci ; 28: e20190516, 2020. graf
Article Dans Anglais | LILACS, BBO | ID: biblio-1090775

Résumé

Abstract This study investigated the effect of a calcium hydroxide (CH) paste (CleaniCal®) containing N-2-methyl pyrrolidone (NMP) as a vehicle on Enterococcus faecalis (E. faecalis) biofilms compared with other products containing saline (Calasept Plus™) or propylene glycol (PG) (Calcipex II®). Methodology Standardized bovine root canal specimens were used. The antibacterial effects were measured by colony-forming unit counting. The thickness of bacterial microcolonies and exopolysaccharides was assessed using confocal laser scanning microscopy. Morphological features of the biofilms were observed using field-emission scanning electron microscopy (FE-SEM). Bovine tooth blocks covered with nail polish were immersed into the vehicles and dispelling was observed. The data were analyzed using one-way analysis of variance and Tukey tests (p<0.05). Results CleaniCal® showed the highest antibacterial activity, followed by Calcipex II® (p<0.05). Moreover, NMP showed a higher antibacterial effect compared with PG (p<0.05). The thickness of bacteria and EPS in the CleaniCal® group was significantly lower than that of other materials tested (p<0.05). FE-SEM images showed the specimens treated with Calasept Plus™ were covered with biofilms, whereas the specimens treated with other medicaments were not. Notably, the specimen treated with CleaniCal® was cleaner than the one treated with Calcipex II®. Furthermore, the nail polish on the bovine tooth block immersed in NMP was completely dispelled. Conclusions CleaniCal® performed better than Calasept Plus™ and Calcipex II® in the removal efficacy of E. faecalis biofilms. The results suggest the effect might be due to the potent dissolving effect of NMP on organic substances.


Sujets)
Animaux , Bovins , Pyrrolidones/pharmacologie , Liquides d'irrigation endocanalaire/pharmacologie , Hydroxyde de calcium/pharmacologie , Enterococcus faecalis/effets des médicaments et des substances chimiques , Biofilms/effets des médicaments et des substances chimiques , Antibactériens/pharmacologie , Chlorure de potassium/pharmacologie , Chlorure de potassium/composition chimique , Pyrrolidones/composition chimique , Liquides d'irrigation endocanalaire/composition chimique , Test de matériaux , Chlorure de calcium/pharmacologie , Chlorure de calcium/composition chimique , Hydroxyde de calcium/composition chimique , Microscopie électronique à balayage , Chlorure de sodium/pharmacologie , Chlorure de sodium/composition chimique , Numération de colonies microbiennes , Reproductibilité des résultats , Analyse de variance , Hydrogénocarbonate de sodium/pharmacologie , Hydrogénocarbonate de sodium/composition chimique , Statistique non paramétrique , Microscopie confocale , Association médicamenteuse
2.
Experimental & Molecular Medicine ; : 757-764, 2009.
Article Dans Anglais | WPRIM | ID: wpr-71507

Résumé

Monocyte chemoattractant protein-1 (MCP1) plays a key role in monocyte/macrophage infiltration to the sub-endothelial space of the blood vessel wall, which is a critical initial step in atherosclerosis. In this study, we examined the intracellular signaling pathway of IL-1beta-induced MCP1 expression using various chemical inhibitors. The pretreatment of a phosphatidylcholine (PC)-specific PLC (PC-PLC) inhibitor (D609), PKC inhibitors, or an NF-kappaB inhibitor completely suppressed the IL-1beta-induced MCP1 expression through blocking NF-kappaB translocation to the nucleus. Pretreatment with inhibitors of tyrosine kinase or PLD partially suppressed MCP1 expression and failed to block nuclear NF-kappaB translocation. These results suggest that IL-1beta induces MCP1 expression through activation of NF-kappaB via the PC-PLC/PKC signaling pathway.


Sujets)
Humains , Transport nucléaire actif/effets des médicaments et des substances chimiques , Aorte/anatomopathologie , Athérosclérose/immunologie , Composés pontés/pharmacologie , Noyau de la cellule/métabolisme , Cellules cultivées , Chimiokine CCL2/biosynthèse , Oestrènes/pharmacologie , Génistéine/pharmacologie , Interleukine-1 bêta/métabolisme , Myocytes du muscle lisse/effets des médicaments et des substances chimiques , Facteur de transcription NF-kappa B/métabolisme , Phospholipases/antagonistes et inhibiteurs , Protein-tyrosine kinases/antagonistes et inhibiteurs , Pyrrolidones/pharmacologie , Protéines recombinantes/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Thiones/pharmacologie
3.
Experimental & Molecular Medicine ; : 92-97, 2008.
Article Dans Anglais | WPRIM | ID: wpr-77110

Résumé

Endothelins (ETs), which were originally found to be potent vasoactive transmitters, were known to be implicated in nervous system, but the mode of mechanism remains unclear. ETs (ET-1, ET-2, and ET-3) were added to HN33 (mouse hippocampal neuron chi neuroblastoma) cells. Among the three types of ET, only ET-1 increased the intracellular calcium levels in a PLC dependent manner with the induction of ERK 1/2 activation. As the result of ET-1 exposure, the survival rate of HN33 cells and the PKCalpha translocation into the plasma membrane were increased. We suggest that ET-1 participated in the neuroprotective effect involving the calcium-PKCalpha-ERK1/2 pathway.


Sujets)
Animaux , Souris , Apoptose/effets des médicaments et des substances chimiques , Calcium/métabolisme , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Cytosol/effets des médicaments et des substances chimiques , Endothéline-1/pharmacologie , Endothéline-2/pharmacologie , Endothéline-3/pharmacologie , Oestrènes/pharmacologie , Extracellular Signal-Regulated MAP Kinases/métabolisme , Immunotransfert , Mitogen-Activated Protein Kinase 1/métabolisme , Mitogen-Activated Protein Kinase 3/métabolisme , Neurones/cytologie , Neuroprotecteurs/pharmacologie , Phosphoprotéines/métabolisme , Protein kinase C-alpha/métabolisme , Transport des protéines/effets des médicaments et des substances chimiques , Pyrrolidones/pharmacologie , Sérum
4.
Southeast Asian J Trop Med Public Health ; 2007 Sep; 38(5): 897-903
Article Dans Anglais | IMSEAR | ID: sea-35789

Résumé

In order to study the role of the cytokine interleukin-3 (IL-3) and its signaling pathways in erythropoiesis of beta-thalassemia/HbE erythroid progenitor cells, CD34 positive cells were isolated from peripheral blood of patients and healthy subjects. After culturing the cells in the presence or absence of IL-3, cell viability was measured by trypan blue staining and apoptotic cells were analyzed by flow cytometry. After 7 days of culture the highest percent erythroid progenitor cell viability was obtained with cells from healthy subjects, while the lowest percentage was found in those from splenectomized beta-thalassemia/HbE. Viability of beta-thalassemia/HbE erythroid progenitor cells in the presence of IL-3 was higher than that of nonsupplemented cells. In addition, specific inhibitors of protein kinase C (Ro-318220), phospholipase C (U-73122) and Janus kinase 2 (AG-490) were used to investigate the involvement of signaling pathways in erythropoiesis. Percent apoptosis of erythroid progenitor cells from splenectomized beta-thalassemia/HbE subjects treated with RO-318220 was higher than those of nonsplenectomized beta-thalassemia/HbE and healthy subjects. Treatment with U-73122 resulted in enhanced percent apoptotic cells from normal and beta-thalassemia/HbE subjects. All these effects were independent of IL-3 treatment.


Sujets)
Adolescent , Adulte , Antigènes CD34/sang , Apoptose/immunologie , Enfant , Précurseurs érythroïdes/effets des médicaments et des substances chimiques , Érythropoïèse/effets des médicaments et des substances chimiques , Oestrènes/pharmacologie , Femelle , Hémoglobine E/immunologie , Humains , Interleukine-3/immunologie , Mâle , Adulte d'âge moyen , Protéine kinase C/antagonistes et inhibiteurs , Pyrrolidones/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , Rate/immunologie , Splénectomie , bêta-Thalassémie/sang
5.
Experimental & Molecular Medicine ; : 185-194, 2007.
Article Dans Anglais | WPRIM | ID: wpr-90614

Résumé

Phytosphingosine-1-phosphate (PhS1P) was found to stimulate an intracellular calcium increase via phospholipase C but not pertussis toxin (PTX)- sensitive G-proteins in L2071 mouse fibroblasts. PhS1P also activated ERK and p38 kinase, and these activations by PhS1P were inhibited by PTX. Moreover, PhS1P stimulated the chemotactic migration of L2071 cells via PTX-sensitive Gi protein(s). In addition, the PhS1P-induced chemotactic migration of L2071 cells was also dramatically inhibited by LY294002 and SB203580 (inhibitors of phosphoinositide 3-kinase and p38 kinase, respectively). L2071 cells are known to express four S1P receptors, i.e., S1P1, S1P2, S1P3, and S1P4, and pretreatment with an S1P1 and S1P3 antagonist (VPC 23019) did not affect on PhS1P-induced chemotaxis. This study demonstrates that PhS1P stimulates at least two different signaling cascades, one is a PTX-insensitive but phospholipase C dependent intracellular calcium increase, and the other is a PTX-sensitive chemotactic migration mediated by phosphoinositide 3-kinase and p38 kinase.


Sujets)
Animaux , Humains , Souris , Phosphatidylinositol 3-kinase/métabolisme , Signalisation calcique/effets des médicaments et des substances chimiques , Chimiotaxie/effets des médicaments et des substances chimiques , Oestrènes/pharmacologie , Extracellular Signal-Regulated MAP Kinases/métabolisme , Fibroblastes/cytologie , Protéines G/métabolisme , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Toxine pertussique/pharmacologie , Phosphorylation/effets des médicaments et des substances chimiques , Pyrrolidones/pharmacologie , ARN messager/génétique , Récepteurs aux lysosphingolipides/génétique , Sphingosine/analogues et dérivés , p38 Mitogen-Activated Protein Kinases/métabolisme
6.
Article Dans Anglais | IMSEAR | ID: sea-19165

Résumé

BACKGROUND & OBJECTIVES: Epileptic seizures have been reported in patients on imipenem/cilastatin (Imi/Cil) therapy. To investigate contribution of N-methyl-D-aspartate (NMDA) receptors in inducing imipenem/cilastatin (Imi/Cil) seizures, the effects of competitive NMDA antagonist, APV [(+/-)-2-amino-5-phosphonovaleric acid], non-competitive NMDA antagonist remacemide [(+/-)-2-amino-N-(1-methyl-1,2-diphenylethyl)-acetamidel, and glycine receptor partial agonist HA-966 [(+/-)-(3-amino-1-hydroxypyrrolid-2-one)] on electroencephalographic (EEG) activity and behaviour were studied in rats. METHODS: Adult male Wistar albino rats were implanted with electrodes and cannulae were placed into the right lateral ventricle. Animals were divided into five groups: (i) saline (icv)+Imi/Cil (ii) APV (0.2 micromol)+Imi/Cil, (iii) APV (0.4 micromol)+Imi/Cil, (iv) remacemide (100 mg/kg, ip)+Imi/Cil, and (v) HA-966 (200 microg, icv)+Imi/Cil. The drugs were administered 30 min before icv injection of Imi/Cil (100/100 microg), and their effects on incidence of seizures, latencies to EEG changes and convulsions, severity, lethality and time to lethal outcome were studied. RESULTS: Imi/Cil provoked complete seizure response in all rats and all animals died within 10-18 min after the injection. EEG epileptiform activity preceded behavioral seizures. Clonic-tonic seizures were characterized by continuous bursts of high frequency high amplitude spikes in the EEG. The dose of 0.2 micromol of APV prolonged only the latency to the first EEG changes, while 0.4 micromol dose significantly influenced all seizure parameters. HA-966 increased only the latency to Imi/Cil-induced convulsions, while remacemide had no significant effect on seizure parameters. INTERPRETATION & CONCLUSION: The results suggested that excitatory neurotransmission contributed to the generation and/or propagation of Imi/Cil-induced seizures in rats, and that the effects of NMDA antagonists depended on a particular binding site within the NMDA receptor complex, and affinity to that site.


Sujets)
Acétamides/pharmacologie , Animaux , Sites de fixation , Cilastatine/toxicité , Électroencéphalographie/effets des médicaments et des substances chimiques , Imipénem/toxicité , Mâle , Pyrrolidones/pharmacologie , Rats , Rat Wistar , Récepteurs du N-méthyl-D-aspartate/métabolisme , Crises épileptiques/induit chimiquement , Valine/analogues et dérivés
7.
Experimental & Molecular Medicine ; : 226-233, 2001.
Article Dans Anglais | WPRIM | ID: wpr-144647

Résumé

Our recent studies have shown that co-activation of Gq and Gi proteins by 5-hydroxytryptamine (5-HT) and adrenaline show synergism in human platelet aggregation. This study was conducted to examine the mechanism(s) of synergistic interaction of 5-HT and platelet activating factor (PAF) in human platelets. We show that PAF, but not 5-HT, increased platelet aggregation in a concentration-dependent manner. However, low concentrations of 5-HT (2 microM) potentiated platelet aggregation induced by subthreshold concentration of PAF (40 nM) indicating a synergistic interaction between the two agonists and this synergism was blocked by receptor antagonists to either 5-HT or PAF. 5-HT also potentiated the effect of PAF on thromboxane A2 (TXA2) formation and phosphorylation of extracellularly regulated mitogen-activated protein kinases (ERK1/2). The synergism of 5-HT and PAF in platelet aggregation was inhibited by calcium (Ca2+) channel blockers, verapamil and diltiazem, phospholipase C (PLC) inhibitor, U73122, cyclooxygenase (COX) inhibitor, indomethacin, and MEK inhibitor, PD98059. These data suggest that synergistic effect of 5-HT and PAF on human platelet aggregation involves activation of PLC/Ca2+, COX and MAP kinase pathways.


Sujets)
Humains , Diltiazem/pharmacologie , Relation dose-effet des médicaments , Synergie des médicaments , Oestrènes/pharmacologie , Flavones/pharmacologie , Techniques in vitro , Indométacine/pharmacologie , Cinétique , Mitogen-Activated Protein Kinases/métabolisme , Phosphorylation/effets des médicaments et des substances chimiques , Facteur d'activation plaquettaire/pharmacologie , Activation plaquettaire/effets des médicaments et des substances chimiques , Agrégation plaquettaire/effets des médicaments et des substances chimiques , Pyrrolidones/pharmacologie , Sérotonine/pharmacologie , Thromboxane A2/biosynthèse , Vérapamil/pharmacologie
8.
Experimental & Molecular Medicine ; : 226-233, 2001.
Article Dans Anglais | WPRIM | ID: wpr-144635

Résumé

Our recent studies have shown that co-activation of Gq and Gi proteins by 5-hydroxytryptamine (5-HT) and adrenaline show synergism in human platelet aggregation. This study was conducted to examine the mechanism(s) of synergistic interaction of 5-HT and platelet activating factor (PAF) in human platelets. We show that PAF, but not 5-HT, increased platelet aggregation in a concentration-dependent manner. However, low concentrations of 5-HT (2 microM) potentiated platelet aggregation induced by subthreshold concentration of PAF (40 nM) indicating a synergistic interaction between the two agonists and this synergism was blocked by receptor antagonists to either 5-HT or PAF. 5-HT also potentiated the effect of PAF on thromboxane A2 (TXA2) formation and phosphorylation of extracellularly regulated mitogen-activated protein kinases (ERK1/2). The synergism of 5-HT and PAF in platelet aggregation was inhibited by calcium (Ca2+) channel blockers, verapamil and diltiazem, phospholipase C (PLC) inhibitor, U73122, cyclooxygenase (COX) inhibitor, indomethacin, and MEK inhibitor, PD98059. These data suggest that synergistic effect of 5-HT and PAF on human platelet aggregation involves activation of PLC/Ca2+, COX and MAP kinase pathways.


Sujets)
Humains , Diltiazem/pharmacologie , Relation dose-effet des médicaments , Synergie des médicaments , Oestrènes/pharmacologie , Flavones/pharmacologie , Techniques in vitro , Indométacine/pharmacologie , Cinétique , Mitogen-Activated Protein Kinases/métabolisme , Phosphorylation/effets des médicaments et des substances chimiques , Facteur d'activation plaquettaire/pharmacologie , Activation plaquettaire/effets des médicaments et des substances chimiques , Agrégation plaquettaire/effets des médicaments et des substances chimiques , Pyrrolidones/pharmacologie , Sérotonine/pharmacologie , Thromboxane A2/biosynthèse , Vérapamil/pharmacologie
10.
Indian J Exp Biol ; 1989 Mar; 27(3): 269-73
Article Dans Anglais | IMSEAR | ID: sea-57982

Résumé

The study was conducted on 64 Charles Foster albino rats which were equally distributed into 8 even-matched groups, following a 2 x 2 x 2 factorial design by varying three independent factors at two levels: nutrition--normal and undernutrition, environmental--enrichment and impoverishment, and drug treatment--vehicle and piracetam (100 mg/kg, ip). Prenatal nutrition was induced by restricting the mother's food intake. The environmental enrichment/impoverishment and the vehicle/drug treatments were given during the postweaning period of the rat pups. The animals were subjected to original and subsequent reversal brightness discrimination learning tests in a single unit T-maze at 8-9 weeks of age. The results indicate that undernutrition and environmental impoverishment significantly attenuated the original discrimination as well as the reversal discrimination learning. Piracetam treatment improved the learning performance of normally reared rats and also attenuated the original and reversal learning deficits induced by prenatal undernutrition and postnatal impoverishment. The results indicate that piracetam may be useful in memory deficits induced by malnutrition.


Sujets)
Analyse de variance , Animaux , Apprentissage discriminatif/effets des médicaments et des substances chimiques , Femelle , Privation alimentaire , Mâle , Troubles nutritionnels/physiopathologie , Piracétam/pharmacologie , Pyrrolidones/pharmacologie , Rats , Lignées consanguines de rats , Privation sensorielle
11.
Indian J Physiol Pharmacol ; 1980 Jul-Sep; 24(3): 227-32
Article Dans Anglais | IMSEAR | ID: sea-107037

Résumé

Piracetam, 2-oxo-1-pyrrolidine acetamide (Nootropil), is a cyclic GABA analogue. As GABA-mimetic compounds have been reported to potentiate haloperidol-induced catalepsy it was decided to study the effect of piracetam on haloperidol-induced catalepsy in rats. Piracetam, in high doses, was found to induce catalepsy while sub-cataleptic doses of piracetam were found to potentiate haloperidol-induced catalepsy. Piracetam, however, failed to antagonise apomorphine stereotypy in rats thereby ruling out the possibility of its possessing dopamine receptor blocking activity. The possible mechanism involved in the induction of catalepsy by piracetam and in the potentiation of haloperidol-induced catalepsy by sub-cataleptic doses of piracetam is discussed on the basis of its chemical relationship to GABA.


Sujets)
Animaux , Apomorphine/pharmacologie , Catalepsie/induit chimiquement , Relation dose-effet des médicaments , Synergie des médicaments , Halopéridol/pharmacologie , Humains , Mâle , Piracétam/pharmacologie , Pyrrolidones/pharmacologie , Rats , Comportement stéréotypé/effets des médicaments et des substances chimiques , Facteurs temps
SÉLECTION CITATIONS
Détails de la recherche